21st Century Olympic Doping
By Robin Donovan,
NEO.LIFE
| 07. 22. 2021
Gene editing for performance enhancement may not be the Tokyo cheat, but we asked the experts how far off it might be.
Photo by Serena Repice Lentini on Unsplash
The 2020 Summer Olympics in Tokyo, finally set to kick off this week, have already been upended. After waiting an additional year to qualify, Games athletes will now compete in largely empty venues in an event sparked not by the running of a torch, but a series of closed-door ceremonies. Meanwhile, athletes hope to avoid joining a growing number of competitors who have tested positive for COVID-19 since arriving in Tokyo. Victors will accept gold medals passed to them on trays. Even the specter of cheating has evolved. As technologies like CRISPR leap ahead, a newer threat looms, unsteadily: gene doping.
The World Anti-Doping Agency (WADA) recently barred U.S. track star Shelby Houlihan from the Olympic trials after she tested positive for steroids—which Houlihan blamed on a pig organ meat burrito. The agency also banned sprinter and gold medal favorite Sha’Carri Richardson after she tested positive for THC. In addition to those traditional banned substances, WADA has long banned genetically modified cells and alterations of genome sequences or gene expression “by any...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...